## MAY 1 0 2000

## Summary of Safety and Effectiveness

Encore Orthopedics®, Inc. 9800 Metric Blvd Austin, TX 78758 512-832-9500

Trade Name: Keystone Hip

Common Name: Cementless hip stem

<u>Classification Name:</u> Hip joint metal/polymer/metal semi-constrained porous coated uncemented prosthesis

<u>Description</u>: The Keystone Hip is available in a variety of proximal bodies and distal stem diameters and length configurations. When viewed in the mediolateral plane the Keystone Hip tapers slightly proximal to distal. The proximal body is trapezoidal in cross-sectional geometry and tapers lateral to medial. The distal stems are cylindrical and the larger sizes have anterior/posterior flutes to decrease the distal stem stiffness.

The Keystone Hip is fabricated from wrought Titanium that conforms to ASTM F136. The outside surface of the proximal body is porous coated with C.P. Titanium beads (ASTM F67) to provide a porous surface. The stem portion is plasma sprayed with CP Titanium. This stem is intended to be press-fit.

This device is modular with the distal stems attached to the bodies via a morse type taper and locking screw.

<u>Intended Use:</u> The Keystone Hip is intended for treatment of patients who are candidates for total hip arthroplasty because the natural femoral head and neck have been affected by osteoarthritis, inflammatory arthritis, traumatic arthritis, rheumatoid arthritis, avascular necrosis or femoral neck fracture, and revision arthroplasty.

<u>Comparable Features to Predicate Device(s):</u> Features comparable to predicate devices include same materials, design and indications.



MAY 1 0 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Debbie De Los Santos Regulatory/Clinical Specialist Encore Orthopedics 9800 Metric Boulevard Austin, Texas 78758

Re: K000521

Trade Name: Keystone Hip

Regulatory Class: II Product Codes: LPH Dated: February 15, 2000 Received: February 16, 2000

Dear Ms. De Los Santos:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Omne R. Vo Miner Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510(k) Number (if know	n): K000521
Device Name: Key	tone Hip
Indications For Use:	
	Keystone Hip Indications For Use
degenerative joint disea correction of functional	of the total hip replacement prosthesis include: noninflammatory including osteoarthritis and avascular necrosis; rheumatoid arthritis; deformity; revision procedures where other treatments or devices have brounion, femoral neck and trochanteric fractures of the proximal femurichich is unmanageable using other techniques. This stem is to be press-
(PLEASE DO NOT W NEEDED)	ITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
C	ncurrence of CDRH, Office of Device Evaluation (ODE)
	(Division Sign-Off) Division of General Restorative Devices  Number K 0 0 0 5 2
Prescription Use	OR Over-The-Counter Use (Optional Format 1-2-96)_